Ventricular Remodeling

• 

  Subject Areas on Research

  • A 26-year-old man with severe right ventricular hypertrophy. 
  • A Genetic Cardiomyocyte Ablation Model for the Study of Heart Regeneration in Zebrafish. 
  • A critical review of hemodynamic changes and left ventricular remodeling after surgical aortic valve replacement and percutaneous aortic valve replacement. 
  • A randomized, double-blind, placebo-controlled trial to evaluate the safety and effectiveness of intracoronary application of a novel bioabsorbable cardiac matrix for the prevention of ventricular remodeling after large ST-segment elevation myocardial infarction: Rationale and design of the PRESERVATION I trial. 
  • Aborted myocardial infarction after primary percutaneous coronary intervention: magnetic resonance imaging insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. 
  • Age Differences in Effects of Sacubitril/Valsartan on Cardiac Remodeling, Biomarkers, and Health Status. 
  • Analysis of ventricular activation using surface electrocardiography to predict left ventricular reverse volumetric remodeling during cardiac resynchronization therapy. 
  • Angiotensin II blockade followed by growth hormone as adjunctive therapy after experimental myocardial infarction. 
  • Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial. 
  • Apolipoprotein E Polymorphism, Cardiac Remodeling, and Heart Failure in the ARIC Study. 
  • Assessment of no-reflow regions using cardiac MRI. 
  • Association Between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction. 
  • Association between morning blood pressure surge and cardiovascular remodeling in treated elderly hypertensive subjects. 
  • Basic and Translational Research in Cardiac Repair and Regeneration: JACC State-of-the-Art Review. 
  • Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study. 
  • Beyond fitness tracking: The use of consumer-grade wearable data from normal volunteers in cardiovascular and lipidomics research. 
  • Bioabsorbable Intracoronary Matrix for Prevention of Ventricular Remodeling After Myocardial Infarction. 
  • Biomarkers, mineralocorticoid receptor antagonism, and cardiorenal remodeling. 
  • Branch Pulmonary Artery Valve Implantation Reduces Pulmonary Regurgitation and Improves Right Ventricular Size/Function in Patients With Large Right Ventricular Outflow Tracts. 
  • Branched-chain amino acid metabolism in heart disease: an epiphenomenon or a real culprit? 
  • Calcific Aortic Valve Disease: Part 2-Morphomechanical Abnormalities, Gene Reexpression, and Gender Effects on Ventricular Hypertrophy and Its Reversibility. 
  • Cardiac Myosin Activator Omecamtiv Mecarbil Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure: The COSMIC-HF Trial. 
  • Cardiac phenotype and angiotensin II levels in AT1a, AT1b, and AT2 receptor single, double, and triple knockouts. 
  • Cardiac remodeling after large ST-elevation myocardial infarction in the current therapeutic era. 
  • Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. 
  • Cell size and communication: role in structural and electrical development and remodeling of the heart. 
  • Central sympathetic blockade ameliorates brain death-induced cardiotoxicity and associated changes in myocardial gene expression. 
  • Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. 
  • Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 1: Clinical Trial Design Principles: A Consensus Document From the Mitral Valve Academic Research Consortium. 
  • Clinical-pathological correlations of BAV and the attendant thoracic aortopathies. Part 1: Pluridisciplinary perspective on their hemodynamics and morphomechanics. 
  • Combined loss of neuronal and endothelial nitric oxide synthase causes premature mortality and age-related hypertrophic cardiac remodeling in mice. 
  • Competitive displacement of phosphoinositide 3-kinase from beta-adrenergic receptor kinase-1 improves postinfarction adverse myocardial remodeling. 
  • Controversies and Challenges of Ventricular Assist Device Therapy. 
  • Coronary bypass surgery with or without surgical ventricular reconstruction. 
  • Cross-sectional relations of lipid concentrations to left ventricular structural attributes. 
  • Cross-sectional relations of multiple biomarkers representing distinct biological pathways to plasma markers of collagen metabolism in the community. 
  • Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial. 
  • Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. 
  • Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction. 
  • Durable scar size reduction due to allogeneic mesenchymal stem cell therapy regulates whole-chamber remodeling. 
  • Effects of amino acid supplementation on left ventricular remodeling in patients with chronic heart failure with decreased systolic function and diabetes mellitus: rationale and design of a magnetic resonance imaging study. 
  • Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. 
  • Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction-Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial. 
  • Electrical pacing counteracts intrinsic shortening of action potential duration of neonatal rat ventricular cells in culture. 
  • Electrophysiological effects of remodeling cardiac gap junctions and cell size: experimental and model studies of normal cardiac growth. 
  • Elucidating the molecular mechanism of cardiac remodeling using a comparative genomic approach. 
  • Emerging Therapies for Congestive Heart Failure. 
  • Energy metabolic reprogramming in the hypertrophied and early stage failing heart: a multisystems approach. 
  • Epicardial Surface Area of Infarction: A Stable Surrogate of Microvascular Obstruction in Acute Myocardial Infarction. 
  • Essential role of Smad3 in infarct healing and in the pathogenesis of cardiac remodeling. 
  • Evaluation of right and left ventricular diastolic filling. 
  • FGF23 and Left Ventricular Hypertrophy in Children with CKD. 
  • FGF23 modifies the relationship between vitamin D and cardiac remodeling. 
  • Familial aggregation of left ventricular geometry and association with parental heart failure: the Framingham Heart Study. 
  • Fill a Gab(1) in cardiac hypertrophy signaling: search a missing link between gp130 and ERK5 in hypertrophic remodeling in heart. 
  • Fluid dynamics of ventricular filling in heart failure: overlooked problems of RV/LV chamber dilatation. 
  • Functional assessment of myoblast transplantation for cardiac repair with magnetic resonance imaging. 
  • G-Protein-Coupled Receptors in Heart Disease. 
  • Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. 
  • Gender differences in molecular remodeling in pressure overload hypertrophy. 
  • Gender differences in postinfarction left ventricular remodeling. 
  • Gender-specific patterns of left ventricular and myocyte remodeling following myocardial infarction in mice deficient in the angiotensin II type 1a receptor. 
  • Genetic Dissection of Cardiac Remodeling in an Isoproterenol-Induced Heart Failure Mouse Model. 
  • Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium. 
  • Genomics and the pathophysiology of heart failure. 
  • Gi alpha 1-mediated cardiac electrophysiological remodeling and arrhythmia in hypertrophic cardiomyopathy. 
  • Gi-biased β2AR signaling links GRK2 upregulation to heart failure. 
  • HFE H63D Polymorphism and the Risk for Systemic Hypertension, Myocardial Remodeling, and Adverse Cardiovascular Events in the ARIC Study. 
  • Heart Failure Duration and Mechanistic Efficacy of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. 
  • Heart Failure and Atrial Fibrillation, Like Fire and Fury. 
  • Heme oxygenase-1 (HO-1) inhibits postmyocardial infarct remodeling and restores ventricular function. 
  • High-resolution imaging of murine myocardial infarction with delayed-enhancement cine micro-CT. 
  • High-risk percutaneous coronary intervention is associated with reverse left ventricular remodeling and improved outcomes in patients with coronary artery disease and reduced ejection fraction. 
  • Impact of Non-Infarct-Related Artery Disease on Infarct Size and Outcomes (from the CRISP-AMI Trial). 
  • Impact of Physiologic Pacing Versus Right Ventricular Pacing Among Patients With Left Ventricular Ejection Fraction Greater Than 35%: A Systematic Review for the 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 
  • Impact of physiologic pacing versus right ventricular pacing among patients with left ventricular ejection fraction greater than 35%: A systematic review for the 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 
  • Implication of right ventricular dysfunction on long-term outcome in patients with ischemic cardiomyopathy undergoing coronary artery bypass grafting with or without surgical ventricular reconstruction. 
  • Implications of Left Ventricular Geometry in Low-Flow Aortic Stenosis: A PARTNER 2 Trial Subanalysis. 
  • Improved left ventricular mass quantification with partial voxel interpolation: in vivo and necropsy validation of a novel cardiac MRI segmentation algorithm. 
  • Inactivation of the Glucose-Dependent Insulinotropic Polypeptide Receptor Improves Outcomes following Experimental Myocardial Infarction. 
  • Incremental prognostic value of echocardiography of left ventricular remodeling and diastolic function in STICH trial. 
  • Infarct healing is a dynamic process following acute myocardial infarction. 
  • Infarct resorption, compensatory hypertrophy, and differing patterns of ventricular remodeling following myocardial infarctions of varying size. 
  • Influence of baseline left ventricular function on the clinical outcome of surgical ventricular reconstruction in patients with ischaemic cardiomyopathy. 
  • Inhibition of Dipeptidyl Peptidase-4 Impairs Ventricular Function and Promotes Cardiac Fibrosis in High Fat-Fed Diabetic Mice. 
  • Inhibition of the cardiomyocyte-specific troponin I-interacting kinase limits oxidative stress, injury, and adverse remodeling due to ischemic heart disease. 
  • Inhibitory effect of angiotensin II type 2 receptor on coronary arterial remodeling after aortic banding in mice. 
  • Insights from the STICH trial: change in left ventricular size after coronary artery bypass grafting with and without surgical ventricular reconstruction. 
  • Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. 
  • Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. 
  • Junctophilin-2 at the intersection of arrhythmia and pathologic cardiac remodeling. 
  • Klotho and phosphate are modulators of pathologic uremic cardiac remodeling. 
  • Lack of Thy1 defines a pathogenic fraction of cardiac fibroblasts in heart failure. 
  • Left Ventricular Hypertrophy Does Not Affect 1-Year Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement. 
  • Left Ventricular Hypertrophy and Clinical Outcomes Over 5 Years After TAVR: An Analysis of the PARTNER Trials and Registries. 
  • Left bundle branch block-induced left ventricular remodeling and its potential for reverse remodeling. 
  • Left ventricular dysfunction: causes, natural history, and hopes for reversal. 
  • Leukocyte iNOS is required for inflammation and pathological remodeling in ischemic heart failure. 
  • Lin28a Regulates Pathological Cardiac Hypertrophic Growth Through Pck2-Mediated Enhancement of Anabolic Synthesis. 
  • MAPK-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart. 
  • Maternal Obesity Affects Cardiac Remodeling and Recovery in Women with Peripartum Cardiomyopathy. 
  • Measures of cardiac repolarization and body position in infants. 
  • Mechanisms and Models in Heart Failure: A Translational Approach. 
  • Mechanotransduction mechanisms for intraventricular diastolic vortex forces and myocardial deformations: part 1. 
  • Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. 
  • Mitochondrial Creatine Kinase Attenuates Pathologic Remodeling in Heart Failure. 
  • Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. 
  • Monocytes prime autoreactive T cells after myocardial infarction. 
  • Myocardial Damage Detected by Late Gadolinium Enhancement Cardiac Magnetic Resonance Is Uncommon in Peripartum Cardiomyopathy. 
  • Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5. 
  • NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF. 
  • Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. 
  • New paradigms in cardiovascular medicine: emerging technologies and practices: perioperative genomics. 
  • Novel role of platelet reactivity in adverse left ventricular remodelling after ST-segment elevation myocardial infarction: The REMODELING Trial. 
  • Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry. 
  • Overexpression of TNNI3K, a cardiac-specific MAPKKK, promotes cardiac dysfunction. 
  • PKM1 Exerts Critical Roles in Cardiac Remodeling Under Pressure Overload in the Heart. 
  • Patterns of left ventricular remodeling in patients with Duchenne Muscular Dystrophy: a cardiac MRI study of ventricular geometry, global function, and strain. 
  • Percutaneous mitral valve repair in the initial EVEREST cohort: evidence of reverse left ventricular remodeling. 
  • Platelet inhibition to target reperfusion injury trial: Rationale and study design. 
  • Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy. 
  • Predictors of mortality and outcomes of therapy in low-flow severe aortic stenosis: a Placement of Aortic Transcatheter Valves (PARTNER) trial analysis. 
  • Prognostic importance of pathophysiologic markers in patients with heart failure and preserved ejection fraction. 
  • Prognostic value of left ventricular apical tissue removed for HeartMate II left ventricular assist device placement. 
  • Protein biomarkers of cardiac remodeling and inflammation associated with HFpEF and incident events. 
  • QRS fusion complex analysis using wave interference to predict reverse remodeling during cardiac resynchronization therapy. 
  • Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan. 
  • Racial/Ethnic Differences in Left Ventricular Structure and Function in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort. 
  • Rationale and design of a randomized controlled trial of allogeneic mesenchymal stem cells in patients with nonischemic cardiomyopathy. 
  • Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure. 
  • Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. 
  • Regional left ventricular function does not predict survival in ischaemic cardiomyopathy after cardiac surgery. 
  • Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure. 
  • Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION. 
  • Relationship between the magnitude of reduction in mitral regurgitation severity and left ventricular and left atrial reverse remodeling after MitraClip therapy. 
  • Renin-angiotensin-aldosterone genotype influences ventricular remodeling in infants with single ventricle. 
  • Retinal arteriolar narrowing and left ventricular remodeling: the multi-ethnic study of atherosclerosis. 
  • Reversal of cardiac remodeling by modulation of adrenergic receptors: a new frontier in heart failure. 
  • Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes. 
  • Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan. 
  • Right ventricular lead location and outcomes among patients with cardiac resynchronization therapy: A meta-analysis. 
  • Right-Sided Cardiac Dysfunction in Heart Failure With Preserved Ejection Fraction and Worsening Renal Function. 
  • Role of p38alpha MAPK in cardiac apoptosis and remodeling after myocardial infarction. 
  • SRC-2 coactivator deficiency decreases functional reserve in response to pressure overload of mouse heart. 
  • Sarcoplasmic reticulum calcium defect in Ras-induced hypertrophic cardiomyopathy heart. 
  • Secondary mitral and tricuspid regurgitation accompanying left ventricular systolic dysfunction: is it important, and how is it treated? 
  • Severity of Remodeling, Myocardial Viability, and Survival in Ischemic LV Dysfunction After Surgical Revascularization. 
  • Sex dependence and temporal dependence of the left ventricular genomic response to pressure overload. 
  • Sex-Based Differences in Outcomes After Mitral Valve Surgery for Severe Ischemic Mitral Regurgitation: From the Cardiothoracic Surgical Trials Network. 
  • Sex-based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan. 
  • Simple regional strain pattern analysis to predict response to cardiac resynchronization therapy: rationale, initial results, and advantages. 
  • Smad3 Signaling Promotes Fibrosis While Preserving Cardiac and Aortic Geometry in Obese Diabetic Mice. 
  • Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling. 
  • Strategies to attenuate pathological remodeling in heart failure. 
  • Stress-activated MAP kinases in cardiac remodeling and heart failure; new insights from transgenic studies. 
  • Surgical treatment of moderate ischemic mitral regurgitation. 
  • Surrogate end points in heart failure trials. 
  • Systems Genetics Approach Identifies Gene Pathways and Adamts2 as Drivers of Isoproterenol-Induced Cardiac Hypertrophy and Cardiomyopathy in Mice. 
  • TASK-1 and TASK-3 channels modulate pressure overload-induced cardiac remodeling and dysfunction. 
  • Targeted anti-IL-1β platelet microparticles for cardiac detoxing and repair. 
  • Targeted overexpression of noncleavable and secreted forms of tumor necrosis factor provokes disparate cardiac phenotypes. 
  • The Effect of the Superior Cavopulmonary Anastomosis on Ventricular Remodeling in Infants with Single Ventricle. 
  • The PARACHUTE IV trial design and rationale: percutaneous ventricular restoration using the parachute device in patients with ischemic heart failure and dilated left ventricles. 
  • The Role for Cardiovascular Remodeling in Cardiovascular Outcomes. 
  • The STICH trial: evidence-based conclusions. 
  • The association between biventricular pacing and cardiac resynchronization therapy-defibrillator efficacy when compared with implantable cardioverter defibrillator on outcomes and reverse remodelling. 
  • The chromatin-binding protein Smyd1 restricts adult mammalian heart growth. 
  • The continuous heart failure spectrum: moving beyond an ejection fraction classification. 
  • The elusive philosopher's stone in young blood. 
  • The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense. 
  • The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. 
  • The nitric oxide donor S-nitroso-N-acetylpenicillamine (SNAP) increases free radical generation and degrades left ventricular function after myocardial ischemia-reperfusion. 
  • The perplexing complexity of cardiac arrhythmias: beyond electrical remodeling. 
  • The right ventricular transcriptome signature in Ossabaw swine with cardiometabolic heart failure: implications for the coronary vasculature. 
  • The role of cytoprotective cytokines in cardiac ischemia/reperfusion injury. 
  • Thrombogenesis in atrial fibrillation: contributing mechanisms and natural history. 
  • Transthyretin V142I Genetic Variant and Cardiac Remodeling, Injury, and Heart Failure Risk in Black Adults. 
  • Treatment of functional mitral valve regurgitation with the permanent percutaneous transvenous mitral annuloplasty system: results of the multicenter international Percutaneous Transvenous Mitral Annuloplasty System to Reduce Mitral Valve Regurgitation in Patients with Heart Failure trial. 
  • Treatment of sleep-disordered breathing in heart failure impacts cardiac remodeling: Insights from the CAT-HF Trial. 
  • Two-Year Outcomes of Surgical Treatment of Moderate Ischemic Mitral Regurgitation. 
  • Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation. 
  • Use of High-Risk Coronary Atherosclerotic Plaque Detection for Risk Stratification of Patients With Stable Chest Pain: A Secondary Analysis of the PROMISE Randomized Clinical Trial. 
  • Vectorcardiographic QRS area is associated with long-term outcome after cardiac resynchronization therapy. 
  • YAP: The nexus between metabolism and cardiac remodeling. 
  • β-Adrenergic receptor antagonists ameliorate myocyte T-tubule remodeling following myocardial infarction. 
• 

  Keywords of People

  • Badea, Cristian Tudorel, Professor in Radiology, Biomedical Engineering
  • Landstrom, Andrew Paul, Associate Professor of Pediatrics, Cell Biology
  • Mentz, Robert John, Associate Professor of Medicine, Medicine, Cardiology
  • Milano, Carmelo Alessio, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, Surgery, Cardiovascular and Thoracic Surgery
  • Milazzo Jr., Angelo Stephen, Professor of Pediatrics, Pediatrics
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. Distinguished Professor, Medicine, Clinical Pharmacology